Baxano Surgical Inc (BAXS) 0.13 $BAXS
Baxano Surgical Completes Financing and Continues Streamlined Business Operations
GlobeNewswire - Thu Sep 25, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, announced that the Company has completed a recent subordinated convertible note financing of approximately $1.5 million to extend its cash runway. In connection with the financing, the Company has also streamlined its business to reduce its operating expenses while maintaining its commercial operations.
BAXS: 0.13 (-0.01)
Baxano Surgical to Explore Strategic Alternatives for Its MIS Spine Business
GlobeNewswire - Thu Sep 18, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company has engaged Houlihan Lokey as its financial advisor to advise it on potential strategic alternatives for the Company's business.
BAXS: 0.13 (-0.01)
Baxano Surgical to Train 35 Surgeons on Advanced MIS Techniques
GlobeNewswire - Fri Sep 12, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company is participating in an MIS-based training course hosted by the International Society for the Advancement of Spine Surgery (ISASS), and co-chaired by Anthony Yeung, MD and James J Yue, MD.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Reports Operating Results for the Second Quarter of 2014, Issues Third Quarter 2014 Guidance
GlobeNewswire - Tue Aug 05, 3:08PM CDT
- Second quarter revenue of $4.7 million, representing year-over-year growth of 20.1% and sequential growth of 5.5% -
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Two New Patents for VEO Direct Lateral and AxiaLIF Minimally Invasive Interbody Fusion Systems
GlobeNewswire - Tue Aug 05, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the United States Patent and Trademark Office has issued two patents on key Baxano Surgical technologies, bringing the company's patent portfolio to 92 patents in the U.S.
BAXS: 0.13 (-0.01)
Baxano Surgical Announces Second Quarter 2014 Earnings Conference Call and Webcast
GlobeNewswire - Thu Jul 24, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it will release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes. Ken Reali, President and Chief Executive Officer and Tim Shannon, Chief Financial Officer, will then conduct a conference call at 4:30 pm ET to review the results.
BAXS: 0.13 (-0.01)
Economic Analysis of Minimally Invasive Spine Fusion Using AxiaLIF Accepted for Publication in the Journal of Managed Care Medicine
GlobeNewswire - Fri Jul 18, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Journal of Managed Care Medicine, a peer-reviewed national publication, has accepted an economic analysis of the AxiaLIF pre-sacral interbody fusion procedure in comparison to transforaminal lumbar interbody fusion (TLIF).
BAXS: 0.13 (-0.01)
Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System
GlobeNewswire - Mon Jun 30, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the first case utilizing the Avance(TM) MIS Pedicle Screw System was recently performed by Dr. Sameer Mathur in Cary, NC. The innovative design of Avance provides for an easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release through the end of third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.
BAXS: 0.13 (-0.01)
Baxano Surgical to Present at JMP Securities Healthcare Conference
GlobeNewswire - Mon Jun 16, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that the Company's CEO, Ken Reali, will present at the JMP Securities Healthcare Conference in New York on June 24, 2014. The Company's presentation is scheduled to begin at 2:00 pm EDT and will be taking place in the Grand Central Ballroom D at The Westin New York Grand Central.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Changes to Executive Management Team
GlobeNewswire - Fri Mar 14, 11:00AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced changes to its executive management team.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Tue Mar 11, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company"
, a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has entered into a definitive agreement with entities affiliated with two institutional investors in connection with a private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock. Prior to the closing of the private placement, the Company is required to obtain stockholder approval to increase the total number of its authorized shares of common stock and to approve the issuance of common stock pursuant to the debentures and warrants.
BAXS: 0.13 (-0.01)
Baxano Surgical Announces Participation in Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Fri Mar 07, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it will participate in the Canaccord Genuity Musculoskeletal Conference on March 11, 2014.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Reports Operating Results for the Fourth Quarter of 2013, Issues First Quarter 2014 Guidance
GlobeNewswire - Fri Mar 07, 2:59AM CST
- Fourth Quarter Revenue Was $6.0 Million -
BAXS: 0.13 (-0.01)
Baxano Surgical Schedules Fourth Quarter 2013 Results Conference Call for Thursday, March 6, 2014
GlobeNewswire - Mon Mar 03, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release fourth quarter 2013 financial and operating results after market close on Thursday, March 6, 2014. Ken Reali, President and Chief Executive Officer of Baxano Surgical, and Tim Shannon, Interim Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
BAXS: 0.13 (-0.01)
Baxano Surgical Sets Date of 2014 Annual Meeting
GlobeNewswire - Fri Feb 07, 11:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced that it will be holding its Annual Meeting of Stockholders on Thursday, April 17, 2014. Stockholders of record at the close of business on Monday, March 10, 2014 will be entitled to notice of and to vote at the Annual Meeting.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Changes to Management Team
GlobeNewswire - Fri Sep 20, 11:00AM CDT
Third Quarter and Full Year Revenue Guidance Reaffirmed
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Schedules Second Quarter 2013 Results Conference Call for Thursday, August 8, 2013
GlobeNewswire - Thu Jul 25, 3:44PM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release second quarter 2013 financial and operating results after market close on Thursday, August 8, 2013. Ken Reali, President and Chief Executive Officer and Joe Slattery, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/eventdetail.cfm?eventid=132615.
BAXS: 0.13 (-0.01)
Abbott Beats on Earnings in 2Q, Reiterates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 17, 8:40AM CDT
Abbott reported second quarter 2013 earnings of 46 cents per share, beating the Zacks Consensus Estimate of 44 cents.
BAXS: 0.13 (-0.01), ABT: 42.20 (-0.19), LMAT: 6.80 (-0.10), ABBV: 56.91 (+0.62)
Abbott Lab's Xience Xpedition in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 11, 4:31PM CDT
Abbott Labs recently announced that it has received approval for the Xience Xpedition Everolimus Eluting Coronary Stent System in Japan.
BSX: 12.45 (+0.42), BAXS: 0.13 (-0.01), ABT: 42.20 (-0.19), LMAT: 6.80 (-0.10)
Baxano Surgical Completes Financing and Continues Streamlined Business Operations
GlobeNewswire - Thu Sep 25, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, announced that the Company has completed a recent subordinated convertible note financing of approximately $1.5 million to extend its cash runway. In connection with the financing, the Company has also streamlined its business to reduce its operating expenses while maintaining its commercial operations.
BAXS: 0.13 (-0.01)
Baxano Surgical to Explore Strategic Alternatives for Its MIS Spine Business
GlobeNewswire - Thu Sep 18, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company has engaged Houlihan Lokey as its financial advisor to advise it on potential strategic alternatives for the Company's business.
BAXS: 0.13 (-0.01)
Baxano Surgical to Train 35 Surgeons on Advanced MIS Techniques
GlobeNewswire - Fri Sep 12, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Company is participating in an MIS-based training course hosted by the International Society for the Advancement of Spine Surgery (ISASS), and co-chaired by Anthony Yeung, MD and James J Yue, MD.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Reports Operating Results for the Second Quarter of 2014, Issues Third Quarter 2014 Guidance
GlobeNewswire - Tue Aug 05, 3:08PM CDT
- Second quarter revenue of $4.7 million, representing year-over-year growth of 20.1% and sequential growth of 5.5% -
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Two New Patents for VEO Direct Lateral and AxiaLIF Minimally Invasive Interbody Fusion Systems
GlobeNewswire - Tue Aug 05, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the United States Patent and Trademark Office has issued two patents on key Baxano Surgical technologies, bringing the company's patent portfolio to 92 patents in the U.S.
BAXS: 0.13 (-0.01)
Baxano Surgical Announces Second Quarter 2014 Earnings Conference Call and Webcast
GlobeNewswire - Thu Jul 24, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that it will release second quarter 2014 financial results on Tuesday, August 5, 2014 after the market closes. Ken Reali, President and Chief Executive Officer and Tim Shannon, Chief Financial Officer, will then conduct a conference call at 4:30 pm ET to review the results.
BAXS: 0.13 (-0.01)
Economic Analysis of Minimally Invasive Spine Fusion Using AxiaLIF Accepted for Publication in the Journal of Managed Care Medicine
GlobeNewswire - Fri Jul 18, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the Journal of Managed Care Medicine, a peer-reviewed national publication, has accepted an economic analysis of the AxiaLIF pre-sacral interbody fusion procedure in comparison to transforaminal lumbar interbody fusion (TLIF).
BAXS: 0.13 (-0.01)
Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System
GlobeNewswire - Mon Jun 30, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the first case utilizing the Avance(TM) MIS Pedicle Screw System was recently performed by Dr. Sameer Mathur in Cary, NC. The innovative design of Avance provides for an easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma. The Avance system will be in limited market release through the end of third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.
BAXS: 0.13 (-0.01)
Baxano Surgical to Present at JMP Securities Healthcare Conference
GlobeNewswire - Mon Jun 16, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that the Company's CEO, Ken Reali, will present at the JMP Securities Healthcare Conference in New York on June 24, 2014. The Company's presentation is scheduled to begin at 2:00 pm EDT and will be taking place in the Grand Central Ballroom D at The Westin New York Grand Central.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Changes to Executive Management Team
GlobeNewswire - Fri Mar 14, 11:00AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced changes to its executive management team.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Tue Mar 11, 6:30AM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) ("Baxano Surgical" or the "Company"
, a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, announced today that it has entered into a definitive agreement with entities affiliated with two institutional investors in connection with a private placement of approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants to purchase 9,428,000 shares of common stock. Prior to the closing of the private placement, the Company is required to obtain stockholder approval to increase the total number of its authorized shares of common stock and to approve the issuance of common stock pursuant to the debentures and warrants. BAXS: 0.13 (-0.01)
Baxano Surgical Announces Participation in Canaccord Genuity Musculoskeletal Conference
GlobeNewswire - Fri Mar 07, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it will participate in the Canaccord Genuity Musculoskeletal Conference on March 11, 2014.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Reports Operating Results for the Fourth Quarter of 2013, Issues First Quarter 2014 Guidance
GlobeNewswire - Fri Mar 07, 2:59AM CST
- Fourth Quarter Revenue Was $6.0 Million -
BAXS: 0.13 (-0.01)
Baxano Surgical Schedules Fourth Quarter 2013 Results Conference Call for Thursday, March 6, 2014
GlobeNewswire - Mon Mar 03, 6:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release fourth quarter 2013 financial and operating results after market close on Thursday, March 6, 2014. Ken Reali, President and Chief Executive Officer of Baxano Surgical, and Tim Shannon, Interim Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/events.cfm.
BAXS: 0.13 (-0.01)
Baxano Surgical Sets Date of 2014 Annual Meeting
GlobeNewswire - Fri Feb 07, 11:30AM CST
Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region, today announced that it will be holding its Annual Meeting of Stockholders on Thursday, April 17, 2014. Stockholders of record at the close of business on Monday, March 10, 2014 will be entitled to notice of and to vote at the Annual Meeting.
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Announces Changes to Management Team
GlobeNewswire - Fri Sep 20, 11:00AM CDT
Third Quarter and Full Year Revenue Guidance Reaffirmed
BAXS: 0.13 (-0.01)
Baxano Surgical, Inc. Schedules Second Quarter 2013 Results Conference Call for Thursday, August 8, 2013
GlobeNewswire - Thu Jul 25, 3:44PM CDT
Baxano Surgical, Inc. (Nasdaq:BAXS) announced today that it plans to release second quarter 2013 financial and operating results after market close on Thursday, August 8, 2013. Ken Reali, President and Chief Executive Officer and Joe Slattery, Chief Financial Officer, will host a conference call starting at 4:30 pm ET on the same day. To listen to the conference call on your telephone, please dial (877) 312-8823 for domestic callers and (253) 237-1182 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or archived recording, use the following link at http://ir.baxanosurgical.com/eventdetail.cfm?eventid=132615.
BAXS: 0.13 (-0.01)
Abbott Beats on Earnings in 2Q, Reiterates Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 17, 8:40AM CDT
Abbott reported second quarter 2013 earnings of 46 cents per share, beating the Zacks Consensus Estimate of 44 cents.
BAXS: 0.13 (-0.01), ABT: 42.20 (-0.19), LMAT: 6.80 (-0.10), ABBV: 56.91 (+0.62)
Abbott Lab's Xience Xpedition in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 11, 4:31PM CDT
Abbott Labs recently announced that it has received approval for the Xience Xpedition Everolimus Eluting Coronary Stent System in Japan.
BSX: 12.45 (+0.42), BAXS: 0.13 (-0.01), ABT: 42.20 (-0.19), LMAT: 6.80 (-0.10)
